View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck &
Transaction expected to close on October 7, 2025 LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to
Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on
RAHWAY, N.J. & RALEIGH, N.C.–( BUSINESS WIRE )– MSD (tradename of Merck & Co., Inc., Rahway, N.J. USA) and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
April 24, 2017 |
CORRESP |
CORRESP |
Other |
|
|
April 24, 2017 |
CORRESP |
CORRESP |
Other |
|
|
April 24, 2017 |
CORRESP |
CORRESP |
Other |
|
|
April 24, 2017 |
UPLOAD |
UPLOAD |
Other |
|
|
April 21, 2017 |
CERTNAS |
CERTNAS |
Other |
|
|
April 19, 2017 |
CERTNAS |
CERTNAS |
Other |
|
|
April 19, 2017 |
Registration of certain classes of securities 12(b) of the Securities Exchange Act |
8-A12B |
Registration Statements |
|
|
April 18, 2017 |
This filing is a pre-effective amendment to an F-1 filing |
F-1/A |
Registration Statements |
|
|
April 18, 2017 |
Registration of depository shares evidenced by American Depository Receipts |
F-6 |
Registration Statements |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
